Osteonecrosis of the jaw after radiation followed by bevacizumab

Dermatol Online J. 2024 Mar 15;30(1). doi: 10.5070/D330163297.

Abstract

Osteonecrosis of the jaw is a recognized complication associated with bevacizumab. Here, we present a patient with squamous cell carcinoma of the tonsil who experienced minimal skin fibrosis following intensity-modulated radiation therapy. Subsequently, the patient developed rectal adenocarcinoma and encountered osteonecrosis of the jaw after receiving two cycles of bevacizumab. Close monitoring, accompanied by thorough examination to detect early signs of osteonecrosis of the jaw, should be considered for patients who have undergone radiation therapy in the head and neck region and are receiving bevacizumab or other medications known to be associated with osteonecrosis of the jaw.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / radiotherapy
  • Antineoplastic Agents, Immunological / adverse effects
  • Bevacizumab* / adverse effects
  • Bevacizumab* / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / radiotherapy
  • Humans
  • Jaw Diseases / chemically induced
  • Male
  • Middle Aged
  • Osteonecrosis / chemically induced
  • Radiotherapy, Intensity-Modulated* / adverse effects
  • Rectal Neoplasms / drug therapy
  • Rectal Neoplasms / radiotherapy
  • Tonsillar Neoplasms* / drug therapy
  • Tonsillar Neoplasms* / radiotherapy